<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35724254</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Characteristics of Mismatch Repair-Deficient Colon Cancer in Relation to Mismatch Repair Protein Loss, Hypermethylation Silencing, and Constitutional and Biallelic Somatic Mismatch Repair Gene Pathogenic Variants.</ArticleTitle><Pagination><StartPage>549</StartPage><EndPage>558</EndPage><MedlinePgn>549-558</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002452</ELocationID><Abstract><AbstractText Label="BACKGROUND">Mismatch repair-deficient colon cancer is heterogeneous. Differentiating inherited constitutional variants from somatic genetic alterations and gene silencing is important for surveillance and genetic counseling.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to determine the extent to which the underlying mechanism of loss of mismatch repair influences molecular and clinicopathologic features of microsatellite instability-high colon cancer.</AbstractText><AbstractText Label="DESIGN">This is a retrospective analysis.</AbstractText><AbstractText Label="SETTINGS">This study was conducted at a comprehensive cancer center.</AbstractText><AbstractText Label="PATIENTS">Patients with microsatellite instability-high colon cancer of stage I, II, or III were included.</AbstractText><AbstractText Label="INTERVENTION">Patients underwent a curative surgical resection.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The main outcome measures were hypermethylation of the MLH1 promoter, biallelic inactivation, constitutional pathogenic variants, and loss of specific mismatch repair proteins.</AbstractText><AbstractText Label="RESULTS">Of the 157 identified tumors with complete genetic analysis, 66% had hypermethylation of the MLH1 promoter, 18% had constitutional pathogenic variants, (Lynch syndrome), 11% had biallelic somatic mismatch repair gene pathogenic variants, and 6% had unexplained high microsatellite instability. The distribution of mismatch repair loss was as follows: MLH1 and PMS2 co-loss, 79% of the tumors; MSH2 and MSH6 co-loss, 10%; MSH6 alone, 3%; PMS2 alone, 2%; other combinations, 2%; no loss, 2%. Tumor mutational burden was lowest in MLH1- and PMS2-deficient tumors. MSH6-deficient tumors had the lowest levels of tumor-infiltrating lymphocytes, lowest MSI scores, and fewest frameshift deletions. Patients with MLH1 promoter hypermethylation were significantly more likely to be older and female and to have right-sided colon lesions than patients with biallelic inactivation. Mutation was the most prevalent second hit in tumors with biallelic inactivation and tumors of patients with Lynch syndrome.</AbstractText><AbstractText Label="LIMITATIONS">This study was limited by potential selection or referral bias, missing data for some patients, and relatively small sizes of some subgroups.</AbstractText><AbstractText Label="CONCLUSIONS">Clinical characteristics of mismatch repair-deficient colon cancer vary with the etiology of microsatellite instability, and its molecular characteristics vary with the affected mismatch repair protein. See Video Abstract at http://links.lww.com/DCR/B984 .</AbstractText><AbstractText Label="CARACTERSTICAS DEL CNCER DE COLON CON DEFICIENCIA EN LA REPARACIN DE ERRORES DE EMPAREJAMIENTO EN RELACIN CON LA PRDIDA DE PROTENAS MMR, SILENCIAMIENTO DE LA HIPERMETILACIN Y LAS VARIANTES PATGENAS SOMTICAS DE GENES MMR CONSTITUCIONAL Y BIALLICO">ANTECEDENTES:El c&#xe1;ncer de colon deficiente en la reparaci&#xf3;n de errores de emparejamiento es heterog&#xe9;neo. La diferenciaci&#xf3;n de las variantes constitucionales heredadas de las alteraciones gen&#xe9;ticas som&#xe1;ticas y el silenciamiento de genes es importante para la vigilancia y el asesoramiento gen&#xe9;tico.OBJETIVO:Determinar hasta qu&#xe9; punto el mecanismo subyacente de p&#xe9;rdida de reparaci&#xf3;n de desajustes influye en las caracter&#xed;sticas moleculares y clinicopatol&#xf3;gicas del c&#xe1;ncer de colon con alta inestabilidad de microsat&#xe9;lites.DISE&#xd1;O:An&#xe1;lisis retrospectivo.ESCENARIO:Centro integral de c&#xe1;ncer.PACIENTES:Pacientes con c&#xe1;ncer de colon con inestabilidad de microsat&#xe9;lites alta en estadio I, II, o III.INTERVENCI&#xd3;N:Resecci&#xf3;n quir&#xfa;rgica con intenci&#xf3;n curativa.PRINCIPALES RESULTADOS Y MEDIDAS:Hipermetilaci&#xf3;n del promotor MLH1, inactivaci&#xf3;n bial&#xe9;lica, variante pat&#xf3;gena constitucional y p&#xe9;rdida de prote&#xed;nas espec&#xed;ficas reparadoras de desajustes.RESULTADOS:De los 157 tumores identificados con un an&#xe1;lisis gen&#xe9;tico completo, el 66 % ten&#xed;a hipermetilaci&#xf3;n del promotor MLH1, el 18 % ten&#xed;a una variante patog&#xe9;nica constitucional (s&#xed;ndrome de Lynch), el 11 % ten&#xed;a variantes patog&#xe9;nicas som&#xe1;ticas bial&#xe9;licas de alg&#xfa;n gen MMR y el 6 % ten&#xed;a una alta inestabilidad de microsat&#xe9;lites sin explicaci&#xf3;n. La distribuci&#xf3;n de la p&#xe9;rdida seg&#xfa;n la prote&#xed;na de reparaci&#xf3;n del desajuste fue la siguiente: p&#xe9;rdida conjunta de MLH1 y PMS2, 79 % de los tumores; co-p&#xe9;rdida de MSH2 y MSH6, 10%; MSH6 solo, 3%; PMS2 solo, 2%; otras combinaciones, 2%; sin p&#xe9;rdida, 2%. La carga mutacional del tumor fue m&#xe1;s baja en los tumores deficientes en MLH1 y PMS2. Los tumores con deficiencia de MSH6 ten&#xed;an los niveles m&#xe1;s bajos de linfocitos infiltrantes de tumores, las puntuaciones m&#xe1;s bajas del sensor de IMS y la menor cantidad de deleciones por cambio de marco. Los pacientes con hipermetilaci&#xf3;n del promotor MLH1 ten&#xed;an significativamente m&#xe1;s probabilidades de ser mayores y mujeres y de tener lesiones en el colon derecho que los pacientes con inactivaci&#xf3;n bial&#xe9;lica. La mutaci&#xf3;n fue el segundo golpe m&#xe1;s frecuente en tumores con inactivaci&#xf3;n bial&#xe9;lica y tumores de pacientes con s&#xed;ndrome de Lynch.LIMITACIONES:Sesgo potencial de selecci&#xf3;n o referencia, datos faltantes para algunos pacientes y tama&#xf1;os relativamente peque&#xf1;os de algunos subgrupos.CONCLUSIONES:Las caracter&#xed;sticas cl&#xed;nicas del c&#xe1;ncer de colon deficiente en reparaci&#xf3;n de desajustes var&#xed;an con la etiolog&#xed;a de la inestabilidad de microsat&#xe9;lites, y sus caracter&#xed;sticas moleculares var&#xed;an con la prote&#xed;na de reparaci&#xf3;n de desajustes afectada. Vea Resumen de video en http://links.lww.com/DCR/B984 . (Traducci&#xf3;n-Dr. Felipe Bellolio ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Keshinro</LastName><ForeName>Ajaratu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganesh</LastName><ForeName>Karuna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanderbilt</LastName><ForeName>Chad</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Firat</LastName><ForeName>Canan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jin K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chin-Tung</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaeger</LastName><ForeName>Rona</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Segal</LastName><ForeName>Neil H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonen</LastName><ForeName>Mithat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology &amp; Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shia</LastName><ForeName>Jinru</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stadler</LastName><ForeName>Zsofia K</ForeName><Initials>ZK</Initials><AffiliationInfo><Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiser</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 CA230213</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 CA009501</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.6.1.3</RegistryNumber><NameOfSubstance UI="D000070976">Mismatch Repair Endonuclease PMS2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.3</RegistryNumber><NameOfSubstance UI="D051718">MutS Homolog 2 Protein</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C536928">Turcot syndrome</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003123" MajorTopicYN="Y">Colorectal Neoplasms, Hereditary Nonpolyposis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053843" MajorTopicYN="N">DNA Mismatch Repair</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053842" MajorTopicYN="N">Microsatellite Instability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070976" MajorTopicYN="N">Mismatch Repair Endonuclease PMS2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051718" MajorTopicYN="N">MutS Homolog 2 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003110" MajorTopicYN="Y">Colonic Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="ANTECEDENTES:">El c&#xe1;ncer de colon deficiente en la reparaci&#xf3;n de errores de emparejamiento es heterog&#xe9;neo. La diferenciaci&#xf3;n de las variantes constitucionales heredadas de las alteraciones gen&#xe9;ticas som&#xe1;ticas y el silenciamiento de genes es importante para la vigilancia y el asesoramiento gen&#xe9;tico.</AbstractText><AbstractText Label="OBJETIVO:">Determinar hasta qu&#xe9; punto el mecanismo subyacente de p&#xe9;rdida de reparaci&#xf3;n de desajustes influye en las caracter&#xed;sticas moleculares y clinicopatol&#xf3;gicas del c&#xe1;ncer de colon con alta inestabilidad de microsat&#xe9;lites.</AbstractText><AbstractText Label="DISE&#xd1;O:">An&#xe1;lisis retrospectivo.</AbstractText><AbstractText Label="AJUSTE:">Centro integral de c&#xe1;ncer.</AbstractText><AbstractText Label="PACIENTES:">Pacientes con inestabilidad de microsat&#xe9;lites-c&#xe1;ncer de colon alto en estadio I, II, or III.</AbstractText><AbstractText Label="INTERVENCI&#xd3;N:">Resecci&#xf3;n quir&#xfa;rgica curativa.</AbstractText><AbstractText Label="PRINCIPALES RESULTADOS Y MEDIDAS:">Hipermetilaci&#xf3;n del promotor MLH1, inactivaci&#xf3;n bial&#xe9;lica, variante pat&#xf3;gena constitucional y p&#xe9;rdida de prote&#xed;nas reparadoras de desajustes espec&#xed;ficos.</AbstractText><AbstractText Label="RESULTADOS:">De los 157 tumores identificados con un an&#xe1;lisis gen&#xe9;tico completo, el 66 % ten&#xed;a hipermetilaci&#xf3;n del promotor MLH1, el 18 % ten&#xed;a una variante patog&#xe9;nica constitucional (s&#xed;ndrome de Lynch), el 11 % ten&#xed;a variantes patog&#xe9;nicas del gen MMR som&#xe1;tico bial&#xe9;lico y el 6 % ten&#xed;a una alta inestabilidad de microsat&#xe9;lites sin explicaci&#xf3;n. La distribuci&#xf3;n de la p&#xe9;rdida por reparaci&#xf3;n del desajuste fue la siguiente: p&#xe9;rdida conjunta de MLH1 y PMS2, 79 % de los tumores; co-p&#xe9;rdida de MSH2 y MSH6, 10%; MSH6 solo, 3%; PMS2 solo, 2%; otras combinaciones, 2%; sin p&#xe9;rdida, 2%. La carga mutacional del tumor fue m&#xe1;s baja en los tumores deficientes en MLH1 y PMS2. Los tumores con deficiencia de MSH6 ten&#xed;an los niveles m&#xe1;s bajos de linfocitos infiltrantes de tumores, las puntuaciones m&#xe1;s bajas del sensor MSI y la menor cantidad de deleciones por cambio de marco. Los pacientes con hipermetilaci&#xf3;n del promotor MLH1 ten&#xed;an significativamente m&#xe1;s probabilidades de ser mayores y mujeres y de tener lesiones en el colon derecho que los pacientes con inactivaci&#xf3;n bial&#xe9;lica. La mutaci&#xf3;n fue el segundo golpe m&#xe1;s frecuente en tumores con inactivaci&#xf3;n bial&#xe9;lica y tumores de pacientes con s&#xed;ndrome de Lynch.</AbstractText><AbstractText Label="LIMITACIONES:">Sesgo potencial de selecci&#xf3;n o referencia, datos faltantes para algunos pacientes y tama&#xf1;os relativamente peque&#xf1;os de algunos subgrupos.</AbstractText><AbstractText Label="CONCLUSIONES:">Las caracter&#xed;sticas cl&#xed;nicas del c&#xe1;ncer de colon deficiente en reparaci&#xf3;n de desajustes var&#xed;an con la etiolog&#xed;a de la inestabilidad de microsat&#xe9;lites, y sus caracter&#xed;sticas moleculares var&#xed;an con la prote&#xed;na de reparaci&#xf3;n de desajustes afectada. Vea Resumen de video en http://links.lww.com/DCR/Bxxx.</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2022.</CopyrightInformation></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>20</Day><Hour>13</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35724254</ArticleId><ArticleId IdType="mid">NIHMS1817670</ArticleId><ArticleId IdType="pmc">PMC9763548</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002452</ArticleId><ArticleId IdType="pii">00003453-202304000-00009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Salem ME, Bodor JN, Puccini A, et al. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. Int J Cancer. 2020;147:2948&#x2013;2956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7530095</ArticleId><ArticleId IdType="pubmed">32449172</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis J, Lefterova MI, Artyomenko A, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel. Clin Cancer Res. 2019;25:7035&#x2013;7045.</Citation><ArticleIdList><ArticleId IdType="pubmed">31383735</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawakami H, Zaanan A, Sinicrope FA. Microsatellite instability testing and its role in the management of colorectal cancer. Curr Treat Options Oncol. 2015;16:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4594190</ArticleId><ArticleId IdType="pubmed">26031544</ArticleId></ArticleIdList></Reference><Reference><Citation>Battaglin F, Naseem M, Lenz HJ, Salem ME. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. Clin Adv Hematol Oncol. 2018;16:735&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7493692</ArticleId><ArticleId IdType="pubmed">30543589</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewish M, Lord CJ, Martin SA, Cunningham D, Ashworth A. Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol. 2010;7:197&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">20177404</ArticleId></ArticleIdList></Reference><Reference><Citation>Farchoukh L, Kuan SF, Dudley B, Brand R, Nikiforova M, Pai RK. MLH1-deficient colorectal carcinoma with wild-type BRAF and MLH1 promoter hypermethylation harbor KRAS Mutations and arise from conventional adenomas. Am J Surg Pathol. 2016;40:1390&#x2013;1399.</Citation><ArticleIdList><ArticleId IdType="pubmed">27438990</ArticleId></ArticleIdList></Reference><Reference><Citation>Parsons MT, Buchanan DD, Thompson B, Young JP, Spurdle AB. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet. 2012;49:151&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">22368298</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HT, Duong HQ. The molecular characteristics of colorectal cancer: implications for diagnosis and therapy. Oncol Lett. 2018;16:9&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6006272</ArticleId><ArticleId IdType="pubmed">29928381</ArticleId></ArticleIdList></Reference><Reference><Citation>Mas-Moya J, Dudley B, Brand RE, et al. Clinicopathological comparison of colorectal and endometrial carcinomas in patients with Lynch-like syndrome versus patients with Lynch syndrome. Hum Pathol. 2015;46:1616&#x2013;1625.</Citation><ArticleIdList><ArticleId IdType="pubmed">26319271</ArticleId></ArticleIdList></Reference><Reference><Citation>Pic&#xf3; MD, Castillejo A, Murcia &#xd3;, et al. Clinical and pathological characterization of Lynch-like syndrome. Clin Gastroenterol Hepatol. 2020;18:368&#x2013;374.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">31220642</ArticleId></ArticleIdList></Reference><Reference><Citation>Sourrouille I, Coulet F, Lefevre JH, et al. Somatic mosaicism and double somatic hits can lead to MSI colorectal tumors. Fam Cancer. 2013;12:27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">22987205</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaanan A, Shi Q, Taieb J, et al. Clinical Outcomes in patients with colon cancer with microsatellite instability of sporadic or familial origin treated with adjuvant FOLFOX with or without cetuximab: a pooled analysis of the PETACC8 and N0147 trials. JCO Precis Oncol. 2020;4:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7446392</ArticleId><ArticleId IdType="pubmed">32923882</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearlman R, Haraldsdottir S, de la Chapelle A, et al. Clinical characteristics of patients with colorectal cancer with double somatic mismatch repair mutations compared with Lynch syndrome. J Med Genet. 2019;56:462&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6748629</ArticleId><ArticleId IdType="pubmed">30877237</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Lee LH, Vyas M, et al. Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade. Mod Pathol. 2019;32:1551&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6849386</ArticleId><ArticleId IdType="pubmed">31175329</ArticleId></ArticleIdList></Reference><Reference><Citation>Middha S, Zhang L, Nafa K, et al. Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data. JCO Precis Oncol. JCO 2017;2017:PO.17.00084. doi: 10.1200/PO.17.00084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/PO.17.00084</ArticleId><ArticleId IdType="pmc">PMC6130812</ArticleId><ArticleId IdType="pubmed">30211344</ArticleId></ArticleIdList></Reference><Reference><Citation>Shia J, Ellis NA, Paty PB, et al. Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol. 2003;27:1407&#x2013;1417.</Citation><ArticleIdList><ArticleId IdType="pubmed">14576473</ArticleId></ArticleIdList></Reference><Reference><Citation>Washington MK, Berlin J, Branton P, et al.; Members of the Cancer Committee, College of American Pathologists. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med. 2009;133:1539&#x2013;1551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901838</ArticleId><ArticleId IdType="pubmed">19792043</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyas M, Firat C, Hechtman JF, et al. Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies. Fam Cancer. 2021;20:201&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8032798</ArticleId><ArticleId IdType="pubmed">33033905</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17:251&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5808190</ArticleId><ArticleId IdType="pubmed">25801821</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen R, Seshan VE. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016;44:e131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5027494</ArticleId><ArticleId IdType="pubmed">27270079</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu B, Ye K, Zhang Q, et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics. 2014;30:1015&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3967115</ArticleId><ArticleId IdType="pubmed">24371154</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato A, Sato N, Sugawara T, et al. Isolated loss of PMS2 Immunohistochemical expression is frequently caused by heterogenous mlh1 promoter hypermethylation in Lynch Syndrome Screening for endometrial cancer patients. Am J Surg Pathol. 2016;40:770&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4885527</ArticleId><ArticleId IdType="pubmed">26848797</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemminger JA, Pearlman R, Haraldsdottir S, et al. Histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome. Hum Pathol. 2018;78:125&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6296362</ArticleId><ArticleId IdType="pubmed">29723603</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu GC, Liu RY, Yan JP, et al. The heterogeneity between Lynch-associated and sporadic MMR deficiency in colorectal cancers. J Natl Cancer Inst. 2018;110:975&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pubmed">29471527</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshinro A, Vanderbilt C, Kim JK, et al. Tumor-infiltrating lymphocytes, tumor mutational burden, and genetic alterations in microsatellite unstable, microsatellite stable, or mutant POLE/POLD1 colon cancer. JCO Precis Oncol. 2021;5:817&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8232557</ArticleId><ArticleId IdType="pubmed">34250404</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HT, Le DT, Duong QH, Tatipamula VB, Van Nguyen B. High frequency of microsatellite instability and its substantial co-existence with KRAS and BRAF mutations in Vietnamese patients with colorectal cancer. Oncol Lett. 2021;21:41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7693389</ArticleId><ArticleId IdType="pubmed">33262833</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocco E, Benhamida J, Middha S, et al. Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF/KRAS Are enriched for targetable kinase fusions. Cancer Res. 2019;79:1047&#x2013;1053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6420871</ArticleId><ArticleId IdType="pubmed">30643016</ArticleId></ArticleIdList></Reference><Reference><Citation>Klarskov L, Holck S, Bernstein I, et al. Challenges in the identification of MSH6-associated colorectal cancer: rectal location, less typical histology, and a subset with retained mismatch repair function. Am J Surg Pathol. 2011;35:1391&#x2013;1399.</Citation><ArticleIdList><ArticleId IdType="pubmed">21836479</ArticleId></ArticleIdList></Reference><Reference><Citation>You JF, Buhard O, Ligtenberg MJ, et al. Tumours with loss of MSH6 expression are MSI-H when screened with a pentaplex of five mononucleotide repeats. Br J Cancer. 2010;103:1840&#x2013;1845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3008611</ArticleId><ArticleId IdType="pubmed">21081928</ArticleId></ArticleIdList></Reference><Reference><Citation>Das A, Sudhaman S, Morgenstern D, et al. Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nat Med. 2022;28:125&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8799468</ArticleId><ArticleId IdType="pubmed">34992263</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>